LOS ANGELES, CA – DECEMBER 10: The sun sets behind the game between the Los Angeles Rams and Philadelphia Eagles at the Los Angeles Memorial Coliseum on December 10, 2017 in Los Angeles, California. (Photo by Kevork Djansezian/Getty Images)The Los Angeles Rams are laying an egg right now, losing 10-0 at home to the Green Bay Packers. Right now, the only thing worse than their performance is the paint job at the Coliseum.USC played at home on Saturday night, losing to Arizona State. That left minimal turnaround for the Coliseum’s grounds crew.They attempted to paint over the USC and Pac-12 logos, but they are all still clearly visible. The field looks like a jumbled mess.The end zone is particularly trippy.I woke up today with orange facepaint in my beard and a huge hangover that sapped my willpower and capability to do anything about it.Anyway this is what the Rams’ field looks like today pic.twitter.com/HKaF6FUVJ1— Rodger Sherman (@rodger) October 28, 2018As you might imagine, the grounds crew is taking heat for this.It would be less embarrassing for the Rams to just play on USC’s field than attempt whatever this paint job is— Patrick Daugherty (@RotoPat) October 28, 2018Rams maintenance paints the field#Rams #nfl #ramsfieldpaint pic.twitter.com/YKysVysXoZ— Uncle Michael (@hectorustwo002) October 28, 2018It continually blows my mind that the grounds crew with #Rams are so utterly unsuccessful with tending to the field, isn’t this the NFL ? this is Not a Pac12 game #ComeOnMan…… and many fields share with college teams #FieldWoes #LAColiseum #GBvsLAR pic.twitter.com/DmBwzVhyFh— desiree astorga (@desiree_astorga) October 28, 2018It’s a shame this awesome game between the Rams and Packers is played on a field that’s a wreck with all this new paint over the college field. It looks awful. No other choice tho until the new stadium.— Geoff Schwartz (@geoffschwartz) October 28, 2018Trying to watch this Rams game but I can’t stop focusing on how bad the field looks! This is an NFL team that’s the best the can do? I’ve seen high school fields that look better. ??♀️ pic.twitter.com/CUkzqD0Gqf— Christina Santiago (@therealXtina80) October 28, 2018Fortunately for the grounds crew, the Rams’ poor play is covering up their shoddy craftsmanship.If LA can’t get things going, they will lose for the first time this season.
Chicago: The specialty drug company AbbVie will spend $63 billion to acquire Allergan, the maker of Botox and other cosmetic treatments. The two pharmaceutical companies have little in common, save for a desire to reinvigorate growth that has sputtered. Shares of AbbVie are down 16 per cent over the past year and shares of Allergan are down 24 per cent. “This is a transformational transaction for both companies and achieves unique and complementary strategic objectives,” said AbbVie CEO and Chairman Richard Gonzalez in a prepared statement Tuesday. Also Read – Maruti cuts production for 8th straight month in Sep”The combination of AbbVie and Allergan increases our ability to continue to deliver on our mission to patients and shareholders.” The maker of the global blockbuster immune disorder treatment Humira will pay $120.30 in cash and a portion of AbbVie stock for each Allergan share. That amounts to $188.24 per share, or a 45 per cent premium to Allergan’s closing price Monday. AbbVie is facing the expiration of patent protection for Humira, which brought in a staggering $20 billion in sales last year. Also Read – Ensure strict implementation on ban of import of e-cigarettes: revenue to CustomsIndustry analysts had been anticipating a move by AbbVie to offset the introduction of generics to an extremely valuable pipeline for the company. “We are unsurprised by the timing and the target of the deal given (AbbVie’s) Humira patent cliff,” wrote Citi analyst Andrew Baum. Shares of Allergan Plc, based in Dublin, Ireland, soared 31.2 per cent in premarket trading Tuesday. AbbVie shareholders will own 83 per cent of the specialty drug company combination after the deal’s completion, while Allergan shareholders will have a 17 per cent stake. Gonzalez will remain chairman and CEO at AbbVie. Two members of Allergan’s board, including chairman and CEO Brent Saunders, will join AbbVie’s board once the deal closes.